TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05352334

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-report Emotional Intelligence test (SSCEIT)
Description: The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
Study: NCT04651088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
Study: NCT06430463

Intervention type: DIAGNOSTIC_TEST
Intervention: pure tone audiometry levels
Description: The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
Study: NCT05128786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-38
Description: Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
Study: NCT05311176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Paclitaxel
Description: Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
Study: NCT05432596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 2.0% w/w
Description: ATI-1777 topical solution 2.0% w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 2.0% w/w
Description: ATI-1777 topical solution 2.0% w/w
Study: NCT04651088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
Study: NCT05432596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 1.0% w/w
Description: ATI-1777 topical solution 1.0% w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 0.5% w/w
Description: ATI-1777 topical solution 0.5% w/w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle topical solution
Study: NCT02688699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EndoClot
Description: All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs.
Study: NCT05740631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocaliva
Description: Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
Study: NCT04880629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline condition
Description: In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
Study: NCT04651088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
Study: NCT05510700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out.
Study: NCT06645665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT04816955

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
Study: NCT05092009

Intervention type: OTHER
Intervention: Tissue and blood
Description: Tissue and blood will be derived from patient during a standard of care procedure
Study: NCT05560659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
Study: NCT05786235

Intervention type: OTHER
Intervention: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
Description: Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.

Intervention type: OTHER
Intervention: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
Description: Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
Study: NCT05848713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement.
Study: NCT04651088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily
Study: NCT04799899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted MBCT
Description: The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Health Enhancement
Description: The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
Study: NCT05942417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echoguided percutaneous neuromodulation plus exercise
Description: This group is taking the EPNM and the exercise program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength program
Description: This group is taking the exercise program
Study: NCT04769414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine fluorouracil
Description: chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly
Study: NCT06452667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet-rich fibin
Description: Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich palsma
Description: Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
Study: NCT06158620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-nasal ketorolac
Description: Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral diclofenac
Description: Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
Study: NCT06780033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-101 - SAD
Description: Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneously on Day 1 after 8 hour fast.
Study: NCT06261346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial keratoplasty
Description: Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial keratoplasty
Description: Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~PRGF incubation lasts 15 minutes. It is a one-time procedure performed on the tissue that will be done in the operating room prior to endothelial keratoplasty.
Study: NCT06267729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD0754
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion.
Study: NCT05765344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via subcutaneous injections.
Study: NCT04880629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction condition
Description: In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
Study: NCT06407349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Board
Description: communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Therapy
Description: Traditional Therapy
Study: NCT05190315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
Study: NCT06794931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: The patient will be instructed to follow the modified Mediterranean diet or his usual diet based on the assigned treatment group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples collection
Description: Additional biological samples will also be collected.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological samples collection
Description: Additional biological samples will also be collected.
Study: NCT06548035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Relaxation Response Resiliency Program (3RP)
Description: The 3RP intervention is an integrated program of relaxation response (RR) eliciting meditation and mindfulness exercises, social support, cognitive skills training, and positive psychology focused on developing skills to reduce the stress response, elicit the relaxation response and enhance resiliency.